Investors looking for stocks in the Medical - Instruments sector might want to consider either Thermo Fisher Scientific (TMO) or Idexx Laboratories (IDXX) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank i ...

In the latest market close, Idexx Laboratories (IDXX) reached $519.81, with a +0.99% movement compared to the previous day. The stock exceeded the S&P 500, which registered a gain of 0.15% for the day. Meanwhile, the Dow experienced a drop of 0.02%, and the technology-dominated Nasdaq saw an increase of 0.32%.Shares of the Animal diagnostic and health care company have depreciated by 6.13% over the course of the past month, underperforming the Medical sector's loss of 4.03% and the S&P 500's gain of 1.65%.T ...

Idexx Laboratories (IDXX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Idexx Laboratories (IDXX) , which belongs to the Zacks Medical - Instruments industry, could be a great candidate to consider.When looking at the last two reports, this Animal diagnostic and health care company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 8.09%, on average, in the last two quarters. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________. COMMISSION FILE NUMBER: 0-19271 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 01-039372 ...

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 29, 10:50 am – 11:30 am EST – Brian McKeon, Executive Vice President and Chief Financial Officer, and Tina Hunt, PhD, Executive Vice President, Strategy, Sector Development and Global Operations, will participate in a fireside chat at the BofA Securities Animal Health Virtual Summit. Monday, March 4, 11:00 am – 11:30 am ...

IDEXX Laboratories, Inc. (IDXX) is likely to grow in the coming quarters, backed by the sustained success of CAG’s recurring diagnostic products and services. The company’s international business performance is gaining from its expanded global commercial capability. However, IDEXX’s operations are prone to macroeconomic challenges and foreign exchange fluctuations.In the past year, this Zacks Rank #3 (Hold) stock has increased 8.9% compared with the 3.7% rise of the industry and 22.1% growth of the S&P 500 ...

IDEXX Laboratories, Inc.’s (IDXX) strong global expansion and improved commercial capability aid growth. However, macroeconomic woes dent growth. The stock carries a Zacks Rank #3 (Hold).IDEXX’s Diagnostics business is one of the fastest-growing areas in the veterinary clinic space since the determination of a patient's health status and the best treatment path often require testing. IDEXX provides advanced diagnostic capabilities that meet veterinarians’ diverse needs through a variety of modalities, inclu ...

Jay Mazelsky - President and Chief Executive Officer Conference Call Participants Chris Schott - JPMorgan Nathan Rich - Goldman Sachs Michael Ryskin - Bank of America Erin Wright - Morgan Stanley Jonathan Block - Stifel Financial Operator Good morning and welcome to the IDEXX Laboratories Fourth Quarter 2023 Earnings Conference Call. As a reminder, today's conference is being recorded. Participating in the call this morning are Jay Mazelsky, President and Chief Executive Officer; Brian McKeon, Chief Financi ...

IDEXX Laboratories, Inc. (IDXX) posted fourth-quarter 2023 earnings per share (EPS) of $2.32, up 13.2% year over year. The figure surpassed the Zacks Consensus Estimate by 9.4%.In the fourth quarter of 2023, comparable constant-currency EPS of $2.34 improved 29% year over year.Full-year 2023 earnings of $10.06 rose 25% from the 2022 level. The figure exceeded the Zacks Consensus Estimate by 1.9%.Revenues in DetailFourth-quarter revenues increased 8.8% year over year to $901.6 million. Organically, growth wa ...